CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,952 | +57.3% | 175,188 | +94.6% | 0.07% | +64.4% |
| Q2 2023 | $5,054 | +19.5% | 90,030 | -3.8% | 0.04% | +18.4% |
| Q1 2023 | $4,231 | +244.8% | 93,539 | +209.9% | 0.04% | +245.5% |
| Q4 2022 | $1,227 | -99.9% | 30,179 | -6.7% | 0.01% | -56.0% |
| Q3 2022 | $2,112,000 | -17.8% | 32,329 | -23.5% | 0.02% | -10.7% |
| Q2 2022 | $2,569,000 | +118.8% | 42,274 | +126.2% | 0.03% | +154.5% |
| Q1 2022 | $1,174,000 | +67.5% | 18,692 | +102.0% | 0.01% | +83.3% |
| Q4 2021 | $701,000 | -67.5% | 9,253 | -52.0% | 0.01% | -73.9% |
| Q3 2021 | $2,160,000 | +33.7% | 19,293 | +93.3% | 0.02% | +43.8% |
| Q2 2021 | $1,616,000 | – | 9,983 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |